Polivy (polatuzumab vedotin): New identified risk of severe infusion site extravasation events

A Dear Healthcare Professional Letter has been issued by Roche Singapore Pte Ltd to update healthcare professionals on the new identified risk of infusion site extravasation with polatuzumab vedotin. Analysis of data from post marketing and clinical settings have provided sufficient evidence of a causal association of the events with polatuzumab vedotin. Healthcare professionals are advised to ensure adequate venous access before initiating infusion and maintain close monitoring throughout administration for signs of extravasation. If extravasation is suspected, the infusion should be stopped immediately. The needle should be withdrawn following a brief aspiration and the affected limb elevated. Appropriate symptomatic management may be initiated as required. Roche will be updating the product label to reflect this risk. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

5 Sep 2025

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.